UCB to Accelerate Innovation and Strategic Partnerships, Divesting Mature Product Portfolio in China Read more
ENHERTU Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Read more
Incyte and Syndax Announce FDA Approval of Niktimvo (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) Read more
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by FDA Read more
Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer Read more